page_banner

products

ACCUGENCE ® Sanguis Glucosum Test velit (Gen strictum FAD-dependens)

Description:

ACCUGENCE ® Sanguis Glucosum Test velit (GDH) flavin sunt adenine dinucleotide (FAD) Glucosum -dependent dehydrogenases test fundatur in domum suam et in opera, denudat et professio usu apud parabilis price.


Product Detail

Product Tags

features:

Lab qualitas est amet probatur Sagaciter
Sample Latin Reading Fast tempus, et minima
Informationis invasio Hematocrit Compensation
Cumque nudaveris patrem Auto test notitia Type
2 patitur Sample Application Within III seconds
Latius temperatus repono
VIII Electrodes
Et nulla Maltosa xylosum Informationis invasio

specification:

Model: SM211
Gas dolor: 0.6-33.3mmol / Q (10-600mg / DL)
Sample Volume 0.7μL
Tempus Lorem: V seconds
Sample type: Tempus totum sanguis (capillaribus venosae)
HCT dolor: 10-70%
Temperature repono: 2-35 ° F
Pandura, vita apertum Book: VI mensibus S
iter PLUTEUM-vita (Unopened) XXIV menses

De nobis:

E-Linkcare Meditech Co, Ltd est a multinational comitatu summus tech built per cooperante UK London inter Sinis et Hangzhou ad suum vestibulum facilities fundatur in Xianju, Zhejiang, a medicinae apparatu Sina, ubi diximus a range de ducens artifices et consilio nostro inter Multi AccugenceTM adipiscing ratio, UBREATH TM Spirometer Ratio etc.,

Quia in diem statutum, e-Linkcare Meditech Co., Ltd speciale in administratione commisit melioremque perpetuas contagiones sectione-ore technicae, humanissimi consilio, reguntur bene faciens ars est quoque et digital integrated mobile solution curis. Non optimum usability contendunt, levior user experientia, continua et innovation ut nostrum missionem.

Cum operantes in variis curis professionales totus super orbis terrarum locis orci, altum videtur diximus developed per varias necessitates intellectum tui. Haec perceptiones, combined extensive nostra scientia, experientia et innovation, nobis auxilium develop punctum-of-solutions cura temptationis in crastino.


  • priorem:
  • Deinde:

  • NOBIS LOQUERE
    Dimitte nobis scribere Read more